GSK's European Rytary ambitions unclear on US setback
This article was originally published in Scrip
Executive Summary
Impax Laboratories' shares dipped as the US FDA issued a complete response letter for Rytary (IPX066), an extended-release capsule formulation of carbidopa-levodopa for the potential treatment of the symptoms of Parkinson’s disease.